Lacrimal passage indwelling administration wearable device and use method

Abstract

The application provides a tear duct indwelling drug delivery wearable device and a use method, and solves the problems of low drug utilization rate, easy tear duct adhesion and poor controllability of drug delivery pressure of existing tear duct indwelling medical devices in the field of ophthalmology; wherein the tear duct indwelling drug delivery wearable device comprises: a circulating flow pipeline, the circulating flow pipeline comprises a three-way pipe, an indwelling pipeline and a backflow pipeline, the three-way pipe comprises a first communication pipe, a second communication pipe and a third communication pipe which are in communication with each other at one end, the backflow pipeline is connected with the first communication pipe and the second communication pipe at two ends, the indwelling pipeline comprises a drug slow-release pipe and a circulating pipe which are in communication with each other at one end, the other end of the drug slow-release pipe is connected with the third communication pipe; the third communication pipe is arranged in the lacrimal canaliculus of a patient, the drug slow-release pipe is arranged in the lacrimal sac, the other end of the circulating pipe is connected with the backflow pipeline outside the body from the nasal cavity of the patient, and a drug flow loop is formed; a head-mounted support and a drug delivery assembly arranged on the head-mounted support.

Description

Technical Field

[0001] This invention relates to the field of ophthalmic medical device technology, and in particular to a lacrimal duct indwelling drug delivery wearable device and its usage method. Background Technology

[0002] The lacrimal duct is a crucial channel for the drainage of tears from the eye. Its structure includes the lacrimal punctum, lacrimal canaliculus, lacrimal sac, and nasolacrimal duct. If it becomes narrowed, blocked, or infected due to inflammation, trauma, surgical trauma, etc., it can lead to symptoms such as epiphora and purulent discharge. In severe cases, it may also cause keratitis and orbital inflammation.

[0003] Existing lacrimal duct placement medical devices have the following shortcomings:

[0004] 1. The utilization rate of topical medication is extremely low:

[0005] During conventional eye drop treatment, the medication can only act on the ocular surface. Less than 5% of the medication can enter the lacrimal duct through the lacrimal punctum, and most of it is quickly washed away by tears into the nasal cavity or throat. It cannot form an effective drug concentration at the site of lacrimal duct lesion (such as the lacrimal sac and lacrimal canaliculus mucosa), resulting in a long treatment cycle and poor effect.

[0006] 2. The lack of a circulation loop design results in poor anti-adhesion effect in the lacrimal ducts.

[0007] Most existing indwelling devices are of the "one-way catheter + external drug capsule" structure, which can only inject drugs into the lacrimal duct in one direction and cannot form a closed drug flow loop. After lacrimal duct surgery or during the inflammatory period, the mucosa is in a fragile state. If the drug cannot fill the entire lacrimal duct, the mucosa is prone to adhesion due to contact friction, leading to treatment failure. Moreover, when administering drugs in one direction, the pressure of the drug in the lacrimal duct is uneven. Some areas accumulate drugs and damage the mucosa, while other areas lack drugs and cannot exert their effect.

[0008] 3. The administration pressure and rate are uncontrollable, posing a safety hazard.

[0009] Existing devices mostly rely on manual squeezing of the drug capsule or simple spring-driven operation for drug delivery, which cannot precisely control the drug release rate and intratubular pressure. Excessive pressure may cause tearing of the lacrimal duct mucosa and drug backflow into the periorbital tissues; insufficient pressure will prevent the drug from filling the lacrimal duct and thus fail to prevent adhesion. Furthermore, the lack of pressure monitoring and feedback mechanisms makes it impossible to adjust the drug delivery parameters according to individual patient differences (such as lacrimal duct width and mucosal sensitivity), resulting in insufficient safety and compatibility. Summary of the Invention

[0010] In view of the shortcomings of the prior art described above, the technical problem to be solved by the present invention is to provide a lacrimal duct indwelling drug delivery wearable device and a method of use, which solves the problems of low drug utilization rate, easy lacrimal duct adhesion and poor controllability of drug delivery pressure in the prior art lacrimal duct indwelling medical devices.

[0011] To address the aforementioned technical problems, the present invention provides a lacrimal duct indwelling drug delivery wearable device, comprising:

[0012] The circulating flow tubing includes a three-way connector, an indwelling tubing, and a return tubing. The three-way connector includes a first connecting tube, a second connecting tube, and a third connecting tube that are interconnected at one end. The two ends of the return tubing are respectively connected to the other ends of the first connecting tube and the second connecting tube. The indwelling tubing includes a drug-releasing tube and a circulating tube that are interconnected at one end. The other end of the drug-releasing tube is connected to the other end of the third connecting tube. The third connecting tube is located in the patient's lacrimal canaliculus, the drug-releasing tube is located in the lacrimal sac, and the other end of the circulating tube exits from the patient's nasal passage and connects to the return tubing, forming a drug flow loop.

[0013] A head-mounted support and a drug delivery assembly disposed on the head-mounted support are provided. The drug delivery assembly includes a drive unit, a drug tube, and a drug delivery structure. The drug tube is loaded with drug, and one end of the drug tube is simultaneously connected to both ends of the return tubing. The drive unit drives the drug delivery structure to move according to a set drug release rate, simultaneously squeezing the drug in the drug tube into both ends of the return tubing. The drug enters the drug sustained-release tube through the first connecting tube and the second connecting tube to maintain the drug pressure in the drug flow circuit, keep each tubing in a full state, prevent lacrimal duct adhesion, and simultaneously release drug through the drug sustained-release tube to treat the affected area.

[0014] As a preferred approach, the drug-release tube has several drug release ports on its wall. The advantage of these ports is that they provide a release channel for the drug, allowing it to directly act on the affected area of ​​the lacrimal sac, avoiding waste caused by drug retention within the tube. The port design ensures that the drug can penetrate evenly into the lacrimal sac mucosa, improving drug absorption efficiency. Compared to tubes without release ports, this design allows for a more direct and efficient exertion of the drug's effect.

[0015] As a more preferred approach, the drug release ports are evenly distributed in a mesh pattern on the wall of the drug sustained-release tube. The advantage of this is that the evenly distributed mesh drug release ports allow the drug to be released evenly from all directions of the sustained-release tube, covering the entire inner wall of the lacrimal sac, avoiding local drug concentration or insufficiency, ensuring that all lesions in the lacrimal sac can be exposed to an effective amount of drug, improving the comprehensiveness and consistency of treatment, and reducing the difference in treatment effect caused by uneven drug administration.

[0016] As a preferred embodiment, the drug-release tube includes an expansion section and a contraction section to adapt to the internal structure of the lacrimal sac. Its advantages lie in the fact that the expansion and contraction sections of the drug-release tube adapt to the irregular structure inside the lacrimal sac, allowing for a close fit to the lacrimal sac wall, reducing gaps between the tube and the lacrimal sac, preventing drug loss through these gaps, and improving drug utilization. Simultaneously, the conformal design reduces the foreign body sensation of the tube within the lacrimal sac, minimizes irritation to the lacrimal sac mucosa, and improves patient comfort.

[0017] As a preferred approach, the circulating flow tubing is made of flexible material. The advantages of this are that flexible materials offer excellent flexibility and extensibility, allowing the tubing to deform naturally with the patient's blinking and head movements. This avoids pressure or scratches on the lacrimal canaliculi, lacrimal sac, and nasal passages caused by rigid tubing, reducing the risk of mucosal damage. Flexible materials also improve the fit between the tubing and the lacrimal and nasal passages, reducing foreign body sensation and increasing patient tolerance for long-term wear.

[0018] As a more preferred embodiment, the drug-pushing structure includes a screw and a pusher toothed disc adapted to the inner diameter of the drug tube. The other end of the drug tube is sealed by a cover plate. The screw is positioned at the central axis of the drug tube, with one end rotatably mounted on the cover plate. The pusher toothed disc is fitted onto the other end of the screw and threadedly connected to it. An internal toothed slideway is formed on the inner wall of the drug tube, engaging with the external teeth of the pusher toothed disc. The driving component rotates the screw, causing the pusher toothed disc to slide along the internal toothed slideway, thereby using the pusher toothed disc to expel the drug from the drug tube into the return pipeline. Its advantages lie in the fact that the threaded engagement between the screw and the pusher toothed disc, combined with the limiting effect of the internal toothed slideway, enables precise control of the drug-pushing speed—when the driving component rotates the screw, the pusher toothed disc moves smoothly along the slideway, avoiding jamming or rate fluctuations during drug delivery, ensuring that the drug is released uniformly at the set rate, meeting the therapeutic dosage requirements. Simultaneously, this structure provides stable transmission, maintains precise drug-pushing performance over a long period, and reduces the probability of equipment failure.

[0019] As a more preferred embodiment, the drug-pushing structure further includes a transmission gear disc. One end of the screw passes through the cover plate and is connected to the transmission gear disc. The driving component drives the transmission gear disc to rotate, which in turn drives the screw to rotate. The advantages are that the addition of the transmission gear disc makes the power transmission between the screw and the driving component more stable. The drug-pushing rate can be flexibly adjusted by changing the gear ratio of the transmission gear disc to suit the rotational speed requirements of different driving components, thus improving the adaptability of the device to different drugs and treatment plans. Furthermore, the transmission gear disc can also buffer the instantaneous impact force of the driving component, protecting the screw and the transmission gear disc, and extending the service life of the drug-pushing structure.

[0020] As a more preferred embodiment, the drug delivery assembly further includes an active gear disc, which is mounted on the output shaft of the drive component and meshes with the transmission gear disc. The active gear disc drives the screw to rotate via the transmission gear disc. The advantages of this design are that the meshing transmission between the active and transmission gear discs is smoother than direct drive, effectively avoiding slippage during power transmission and ensuring that the rotational speed of the drive component is accurately converted into the screw's rotational speed, further improving the stability of the drug delivery rate. The meshing structure also facilitates later maintenance—if a gear disc wears out, it can be replaced individually without replacing the entire drug delivery assembly, reducing maintenance costs.

[0021] As a preferred approach, the sidewall of the medication tube has a medication replenishment port for refilling the medication. This allows for direct medication replenishment without disassembling the device or interrupting medication administration, avoiding treatment interruptions caused by tubing replacement and ensuring continuous medication delivery. Simultaneously, the replenishment design reduces the use of medication consumables, lowers the cost of long-term treatment for patients, and improves the ease of use of the device.

[0022] As a preferred option, the head-mounted support is an eyeglass frame structure. Its advantages lie in its conformity to everyday wearing habits, ease of use, and the fact that patients can use it without needing to learn complex techniques. The eyeglass frame is aesthetically pleasing and discreet, reducing the psychological burden on patients, and it does not affect daily vision, work, or social interactions, thus enhancing the device's practicality and patient acceptance.

[0023] As a preferred option, the headband is an elastic headband structure. Its advantages lie in its good elasticity, allowing it to adapt to patients with different head circumferences, ensuring a stable fit and preventing the device from slipping due to head movement. The elastic material conforms to the head's contours, providing even pressure during wear and preventing localized pressure on the head, thus improving comfort during long-term wear, making it especially suitable for patients requiring prolonged treatment.

[0024] As a more preferred approach, the lacrimal duct indwelling drug delivery wearable device further includes a pressure sensor and a control component electrically connected to the drive element. The pressure sensor is disposed in the drug delivery tube and connected to the control component. The control component controls the rate at which the drive element releases the drug based on the drug pressure obtained by the pressure sensor, compared with a preset pressure. The advantage is that the pressure sensor monitors the drug delivery tube pressure in real time, and the control component adjusts the drive element rate based on the pressure data, forming a closed-loop control of "pressure monitoring - rate adjustment": when the pressure is too high, the drug delivery rate is reduced to avoid damaging the lacrimal duct; when the pressure is too low, the rate is increased to ensure the tubing is full and prevents adhesion. This intelligent adjustment function ensures treatment safety, maintains the stability of drug delivery effect, and reduces the workload of manual monitoring.

[0025] To address the aforementioned problems, the present invention also provides a method for using a lacrimal duct indwelling drug delivery wearable device, comprising:

[0026] First, the guide wire is inserted into the tee tube from the opening of the first connecting tube, and then passes through the third connecting tube and the indwelling tube in sequence, and finally exits from the other end of the circulation tube;

[0027] The patient's lacrimal canaliculus is opened using a guidewire, while the third connecting tube and the drug release tube are sequentially placed in the patient's lacrimal canaliculus and lacrimal sac. Finally, the circulation tube is driven to pass out of the patient's nasal passage.

[0028] Connect the other end of the circulation pipe to the return pipe;

[0029] Next, the headband is worn on the patient's head, the drug delivery component is fixed on the headband, and the drug delivery component is connected to the return tubing;

[0030] The drug delivery component is activated, and the drug delivery mechanism is driven to move according to the drug release set rate, so that the drug in the drug tube is simultaneously squeezed into both ends of the return line. The drug is then released through the drug release tube to treat the affected area.

[0031] As described above, the lacrimal duct indwelling drug delivery wearable device and its method of use of the present invention have the following beneficial effects:

[0032] The indwelling tubing of this invention's lacrimal duct indwelling drug delivery wearable device forms a drug flow loop that maintains drug pressure within the loop through the drug delivery components, ensuring that each tubing is always full. This fundamentally avoids adhesions in the lacrimal duct caused by emptiness or insufficient drug solution, thus ensuring treatment safety. The drug-releasing tube is precisely placed in the lacrimal sac, allowing direct drug release to the affected area and improving drug efficacy. The headband facilitates device wear, and the drive unit pushes the drug at a set rate, achieving standardized and precise drug delivery, reducing human error, and balancing therapeutic efficacy with ease of use. Simultaneously, the drug forms a closed-loop flow through the circulation and return tubing, which not only maintains uniform drug concentration but also flushes inflammatory debris and secretions from the lacrimal duct through hydrodynamic action. This dynamic flushing mechanism is similar to the therapeutic effect of lacrimal duct irrigation but eliminates the need for frequent medical procedures, reducing patient discomfort and infection risks.

[0033] The guidewire-assisted catheter insertion step in the method of using the lacrimal duct indwelling drug delivery wearable device of this invention can accurately guide the indwelling catheter into the lacrimal canaliculi and lacrimal sac and out through the nasal passage, avoiding damage to the lacrimal duct tissue caused by blind operation, and improving the success rate and safety of catheter implantation. The steps are clear and the process is standardized, making it easy for medical staff to quickly master the operation method and lowering the threshold for clinical use; at the same time, the clear drug delivery initiation steps ensure that the treatment is carried out according to the standard procedure, ensuring the consistency of drug delivery effect.

[0034] In summary, the lacrimal duct indwelling drug delivery wearable device and method of use of the present invention solves the problems of low drug utilization, easy lacrimal duct adhesion, and poor controllability of drug delivery pressure in the prior art by using a drug flow circuit and maintaining a constant pressure environment in the flow circuit. Attached Figure Description

[0035] Figure 1 The diagram shown is a partial schematic of the lacrimal duct indwelling drug delivery wearable device of the present invention.

[0036] Figure 2 The diagram shown is an overall schematic of the lacrimal duct indwelling drug delivery wearable device of the present invention.

[0037] Figure 3 This is a schematic diagram of the lacrimal duct indwelling drug delivery wearable device of the present invention from another perspective;

[0038] Figure 4 The diagram shows the drug delivery tube and drug delivery components of the lacrimal duct indwelling drug delivery wearable device of the present invention.

[0039] Component designation explanation

[0040] 1 Circulating flow pipeline 11 Tee pipe 111 First connecting pipe 112 Second connecting pipe 113 Third connecting pipe 12 Indwelling pipeline 121 Drug sustained-release tube 121a Expansion phase 121b contraction segment 121c Drug release port 122 Circulation pipe 13 Return pipe 131 feed pipe 2 Headband 3 Drug delivery components 31 Drive components 311 drive gear plate 32 Drug delivery structure 321 screw 322 Drive the gear disc 322a external teeth 323 transmission gear disc 33 Drug administration 331 cover plate 332 roof 333 Internal toothed slide 334 Medication supplement 335 plug Detailed Implementation

[0041] The following specific embodiments illustrate the implementation of the present invention. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification.

[0042] It should be understood that the structures, proportions, sizes, etc., illustrated in the accompanying drawings are merely for illustrative purposes to aid those skilled in the art and to facilitate understanding and reading. They are not intended to limit the implementation of the invention and therefore have no substantial technical significance. Any modifications to the structure, changes in proportions, or adjustments to the size, without affecting the effectiveness and purpose of the invention, should still fall within the scope of the technical content disclosed in the invention. The following detailed description should not be considered restrictive, and the scope of the embodiments of this application is limited only by the claims of the published patents. The terminology used herein is for describing specific embodiments only and is not intended to limit the application. Spatial terms, such as "upper," "lower," "left," "right," "below," "below," "lower part," "above," "upper part," etc., may be used in the text to illustrate the relationship between one element or feature shown in the figures and another element or feature.

[0043] In this invention, unless otherwise explicitly specified and limited, the terms "installation," "connection," "linking," "fixing," and "holding" should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral connection; they can refer to a mechanical connection or an electrical connection; they can refer to a direct connection or an indirect connection through an intermediate medium; and they can refer to the internal connection of two components. Those skilled in the art can understand the specific meaning of the above terms in this invention according to the specific circumstances.

[0044] Furthermore, as used herein, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context indicates otherwise. It should be further understood that the terms “comprising,” “including,” indicate the presence of the stated feature, operation, element, component, item, kind, and / or group, but do not preclude the presence, occurrence, or addition of one or more other features, operations, elements, components, items, kinds, and / or groups. The terms “or” and “and / or” as used herein are interpreted as inclusive, or mean any one or any combination thereof. Thus, “A, B, or C” or “A, B, and / or C” means “any one of: A; B; C; A and B; A and C; B and C; A, B, and C.” Exceptions to this definition arise only when combinations of elements, functions, or operations are inherently mutually exclusive in some manner.

[0045] like Figures 1 to 4 As shown, the present invention provides a lacrimal duct indwelling drug delivery wearable device, comprising:

[0046] A circulating flow tubing 1 includes a three-way connector 11, an indwelling tubing 12, and a return tubing 13. The three-way connector 11 includes a first connecting tube 111, a second connecting tube 112, and a third connecting tube 113, all interconnected at one end. The two ends of the return tubing 13 are connected to the other ends of the first connecting tube 111 and the second connecting tube 112, respectively. The indwelling tubing 12 includes a drug-releasing tube 121 and a circulating tube 122, both interconnected at one end. The other end of the drug-releasing tube 121 is connected to the other end of the third connecting tube 113. The third connecting tube 113 is located in the patient's lacrimal canaliculus, the drug-releasing tube 121 is located in the lacrimal sac, and the other end of the circulating tube 122 extends out of the patient's nasal passage and connects to the return tubing 13, forming a drug flow loop.

[0047] The headband 2 and the drug delivery assembly 3 disposed on the headband 2 are described. The drug delivery assembly 3 includes a drive 31, a drug tube 33, and a drug delivery structure 32. The drug tube 33 is loaded with drug. One end of the drug tube 33 is simultaneously connected to both ends of the return pipeline 13. The drive 31 drives the drug delivery structure 32 to move according to the drug release set rate, squeezing the drug in the drug tube 33 into both ends of the return pipeline 13. The drug enters the drug sustained-release tube 121 through the first connecting tube 111 and the second connecting tube 112 to maintain the drug pressure in the drug flow circuit, keep each pipeline in a full state, prevent lacrimal duct adhesion, and release the drug through the drug sustained-release tube 121 to treat the affected area.

[0048] To better illustrate the lacrimal duct indwelling drug delivery wearable device of the present invention, the following specific application will be used as an example: The drug flow loop formed by the indwelling tubing 12 of the lacrimal duct indwelling drug delivery wearable device of the present invention can maintain the drug pressure within the loop through the drug delivery component 3, ensuring that each tubing is always full, fundamentally avoiding adhesion of the lacrimal duct due to emptiness or insufficient drug solution, and ensuring treatment safety. The drug sustained-release tube 121 is precisely placed in the lacrimal sac, which can directly release the drug to the affected area, improving the drug action efficiency; the headband 2 facilitates the wearing of the device, and the drive component 31 pushes the drug at a set rate, realizing standardized and precise drug delivery, reducing human operation errors, and balancing treatment effect and ease of use; at the same time, the drug forms a closed loop flow through the circulation tube 122 and the return tube 13, which not only maintains the uniformity of drug concentration, but also flushes inflammatory debris and secretions in the lacrimal duct through hydrodynamic action. This dynamic flushing mechanism is similar to the therapeutic effect of lacrimal duct irrigation, but does not require frequent medical operations, reducing patient pain and infection risk.

[0049] In some possible embodiments of the present invention, such as Figure 1 as well as Figure 4 As shown, one end of the medicine tube 33 is connected to both ends of the return pipeline 13 through two feed pipes 131.

[0050] As a more preferred approach, the drug-release tube 121 has several drug release ports 121c on its wall. The advantage of this is that the drug release ports 121c on the tube wall provide a release channel for the drug, allowing the drug inside the tube to directly act on the affected area of ​​the lacrimal sac, avoiding waste caused by drug retention within the tube. The design of the release ports ensures that the drug can penetrate evenly into the lacrimal sac mucosa, improving drug absorption efficiency. Compared to tubes without release ports, this allows for a more direct and efficient exertion of the drug's effect.

[0051] In some possible embodiments of the present invention, such as Figure 1 As shown, the drug release ports 121c are evenly distributed in a mesh pattern on the wall of the drug sustained-release tube 121. The beneficial effect is that the evenly distributed mesh drug release ports 121c allow the drug to be released evenly from all directions of the sustained-release tube, covering the entire inner wall of the lacrimal sac, avoiding local drug concentration or insufficient dosage, ensuring that all lesion sites in the lacrimal sac can come into contact with the effective amount of drug, improving the comprehensiveness and consistency of treatment, and reducing the difference in treatment effect caused by uneven drug administration.

[0052] In some possible embodiments of the present invention, such as Figure 1 as well as Figure 3 As shown, the drug-releasing tube 121 includes an expansion section 121a and a contraction section 121b to adapt to the internal structure of the lacrimal sac. Its beneficial effect is that the expansion section 121a and the contraction section 121b of the drug-releasing tube 121 adapt to the irregular internal structure of the lacrimal sac, allowing for a close fit to the lacrimal sac wall, reducing the gap between the tube and the lacrimal sac, preventing drug loss through the gap, and improving drug utilization. Simultaneously, the conformal design reduces the foreign body sensation of the tube within the lacrimal sac, reduces irritation to the lacrimal sac mucosa, and improves patient comfort.

[0053] In some possible embodiments of the present invention, the circulating flow tubing 1 is made of flexible material. The advantage of this is that the flexible material provides excellent flexibility and extensibility, allowing it to deform naturally with the patient's blinking, head movements, and other actions. This avoids pressure or scratches on the lacrimal canaliculi, lacrimal sac, and nasal passages caused by rigid tubing, reducing the risk of mucosal damage. The flexible material also improves the fit between the tubing and the lacrimal and nasal passages, reducing foreign body sensation and increasing the patient's tolerance for long-term wear.

[0054] In some possible embodiments of the present invention, such as Figure 3As shown, the pushing structure 32 includes a screw 321 and a pushing gear 322 adapted to the inner diameter of the medicine tube 33. The other end of the medicine tube 33 is sealed by a cover plate 331. The screw 321 is located at the central axis of the medicine tube 33, and one end of the screw 321 is rotatably mounted on the cover plate 331. The pushing gear 322 is sleeved on the other end of the screw 321 and threadedly connected to the screw 321. The inner wall of the medicine tube 33 has an internal tooth slide 333 that engages with the external teeth 322a of the pushing gear 322. The driving member 31 drives... The rotation of the screw 321 causes the pusher toothed disc 322 to slide along the internal toothed slideway 333, thereby using the pusher toothed disc 322 to expel the drug from the drug tube 33 into the return pipe 13. Its beneficial effect lies in the fact that the threaded engagement between the screw 321 and the pusher toothed disc 322, combined with the limiting effect of the internal toothed slideway 333, enables precise control of the drug delivery speed. When the drive component 31 drives the screw 321 to rotate, the pusher toothed disc 322 moves smoothly along the slideway, avoiding jamming or rate fluctuations during drug delivery, ensuring that the drug is released uniformly at the set rate, meeting the therapeutic dosage requirements. Simultaneously, this structure provides stable transmission, maintains precise drug delivery performance over a long period, and reduces the probability of equipment failure.

[0055] In some possible embodiments of the present invention, such as Figure 3 As shown, the medicine tube 33 also includes a top plate 332 covering one end of the medicine tube 33. One end of the feed pipe 131 passes through the top plate 332 and communicates with the inner cavity of the medicine tube 33, and the other end is communicated with the return pipe 13.

[0056] In some possible embodiments of the present invention, such as Figure 1 as well as Figure 3 As shown, the drug-pushing structure 32 also includes a transmission gear disk 323. One end of the screw 321 passes through the cover plate 331 and is connected to the transmission gear disk 323. The driving component 31 drives the transmission gear disk 323 to rotate, which in turn drives the screw 321 to rotate. The beneficial effect is that the addition of the transmission gear disk 323 makes the power transmission between the screw 321 and the driving component 31 more stable. By adjusting the tooth ratio of the transmission gear disk 323 to adapt to the different speed requirements of the driving component 31, the drug-pushing rate can be flexibly adjusted, improving the adaptability of the equipment to different drugs and treatment plans. Furthermore, the transmission gear disk 323 can also buffer the instantaneous impact force of the driving component 31, protecting the screw 321 and the pushing gear disk 322, and extending the service life of the drug-pushing structure 32.

[0057] In some possible embodiments of the present invention, such as Figure 1As shown, the drug delivery assembly 3 also includes an active gear disc 311, which is mounted on the output shaft of the drive component 31 and meshes with the transmission gear disc 323. The active gear disc 311 drives the screw 321 to rotate via the transmission gear disc 323. The beneficial effect is that the meshing transmission between the active gear disc 311 and the transmission gear disc 323 is smoother than direct drive, effectively avoiding slippage during power transmission and ensuring that the rotational speed of the drive component 31 is accurately converted into the rotational speed of the screw 321, further improving the stability of the drug delivery rate. The meshing structure also facilitates later maintenance—if a gear disc wears, it can be replaced individually without replacing the entire drug delivery assembly, reducing maintenance costs. Furthermore, in this embodiment, the drive component 31 is an electric motor, and the active gear disc 311 is mounted on the output shaft of the electric motor.

[0058] In some possible embodiments of the present invention, such as Figure 1 As shown, the drug tube 33 has a drug replenishment port 334 on its side wall for replenishing the drug. The advantage of this is that the drug replenishment port 334 on the side wall of the drug tube 33 allows for direct drug replenishment without disassembling the device or interrupting drug administration, avoiding treatment interruptions caused by replacing the drug tube 33 and ensuring continuous drug administration. Simultaneously, the replenishment design reduces the use of consumable drug tubes 33, lowering the cost of long-term treatment for patients and improving the ease of use of the device. Furthermore, in this embodiment, the drug tube 33 also includes a plug 335 for sealing the drug replenishment port 334, facilitating the outflow of necessary medication while replenishing.

[0059] In some possible embodiments of the present invention, such as Figure 1 As shown, the head-mounted support 2 has an eyeglass frame structure. Its advantages lie in the fact that the eyeglass frame structure of the head-mounted support 2 conforms to the daily wearing habits of the general public, is simple to wear and operate, and patients can use it without learning complicated methods. The eyeglass frame is aesthetically pleasing and highly discreet, reducing the psychological burden on patients when wearing it. Furthermore, it does not affect daily vision, work, or social interactions, thus improving the practicality of the device and patient acceptance.

[0060] In some possible embodiments of the present invention, the headband 2 is an elastic headband structure; its advantages are that the elastic headband structure has good elasticity, can adapt to patients with different head circumferences, ensures the stability of the support, and prevents the device from slipping off due to head movement. The elastic material conforms to the contour of the head, and the pressure is even when worn, without causing local pressure on the head, improving the comfort of long-term wear, and is especially suitable for patients who need to wear the device for treatment for a long time.

[0061] In some possible embodiments of the present invention, the lacrimal duct indwelling drug delivery wearable device further includes a pressure sensor and a control component electrically connected to the drive element 31. The pressure sensor is disposed in the drug delivery tube 33 and connected to the control component. The control component controls the rate at which the drive element 31 releases the drug based on the drug internal pressure obtained by the pressure sensor and a preset pressure. The beneficial effect is that the pressure sensor monitors the internal pressure of the drug delivery tube 33 in real time, and the control component adjusts the rate of the drive element 31 based on the pressure data, forming a closed-loop control of "pressure monitoring - rate adjustment": when the pressure is too high, the drug delivery rate is reduced to avoid damage to the lacrimal duct; when the pressure is too low, the rate is increased to ensure the tube is full and prevents adhesion. This intelligent adjustment function ensures treatment safety and maintains the stability of the drug delivery effect, reducing the workload of manual monitoring.

[0062] To address the aforementioned problems, the present invention also provides a method for using a lacrimal duct indwelling drug delivery wearable device, comprising:

[0063] First, the guide wire is inserted into the three-way tube 11 from the opening of the first connecting tube 111, and then passes through the third connecting tube 113 and the indwelling tube 12 in sequence, and finally exits from the other end of the circulation tube 122.

[0064] The patient's lacrimal canaliculus is opened using a guidewire, while the third connecting tube 113 and the drug release tube 121 are sequentially placed in the patient's lacrimal canaliculus and lacrimal sac. Finally, the circulation tube 122 is driven to pass out of the patient's nasal passage.

[0065] Connect the other end of the circulation pipe 122 to the return pipe 13;

[0066] Next, the headband 2 is worn on the patient's head, the drug delivery component 3 is fixed on the headband 2, and the drug delivery component 3 is connected to the return tubing 13;

[0067] The drug delivery component 3 is activated, and the drug delivery structure 32 is driven to move according to the drug release set rate, so that the drug in the drug tube 33 is squeezed into both ends of the return pipe 13 at the same time, and the drug release tube 121 is used to release the drug to treat the affected area.

[0068] To better illustrate the usage of the lacrimal duct indwelling drug delivery wearable device of the present invention, the following specific application will be used as an example: The guidewire-assisted implantation step in the usage method of the lacrimal duct indwelling drug delivery wearable device of the present invention can precisely guide the indwelling catheter 12 into the lacrimal canaliculus and lacrimal sac and out through the nasal passage, avoiding damage to the lacrimal duct tissue caused by blind operation, and improving the success rate and safety of catheter implantation. The steps are clear and the process is standardized, making it easy for medical personnel to quickly master the operation method and lowering the threshold for clinical use; at the same time, the clearly defined drug delivery initiation steps ensure that treatment is carried out according to the standard procedure, guaranteeing the consistency of drug delivery effect.

[0069] In summary, the lacrimal duct indwelling drug delivery wearable device and method of use of the present invention solves the problems of low drug utilization, easy lacrimal duct adhesion, and poor controllability of drug delivery pressure in the prior art by using a drug flow circuit and maintaining a constant pressure environment in the flow circuit.

[0070] As described above, the lacrimal duct indwelling drug delivery wearable device and its method of use of the present invention have the following beneficial effects:

[0071] 1. Drug flow loop design

[0072] The drug flow loop formed by the circulating flow tubing 1 can maintain the drug pressure within the loop, ensuring that each tubing is always full, avoiding adhesions in the lacrimal duct due to emptiness or insufficient drug solution, and ensuring treatment safety.

[0073] 2. Precision drug delivery

[0074] The drug-releasing tube 121 is precisely placed in the lacrimal sac, which can directly release the drug to the affected area and improve the efficiency of drug action; the head-mounted bracket 2 facilitates the wearing of the device, and the drive component 31 pushes the drug at a set rate to achieve standardized and precise drug delivery and reduce human operation errors.

[0075] 3. Dynamic flushing mechanism

[0076] The drug flows in a closed loop through the circulation tube 122 and the return tube 13, which not only maintains the uniformity of drug concentration, but also flushes out inflammatory debris and secretions in the lacrimal duct through hydrodynamic action, similar to the therapeutic effect of lacrimal duct irrigation, but without the need for frequent medical operations, reducing patient pain and infection risk.

[0077] 4. Drug release port 121c design

[0078] The drug release port 121c on the wall of the drug sustained-release tube 121 provides a release channel for the drug, allowing the drug in the tube to act directly on the affected area of ​​the lacrimal sac, avoiding waste caused by drug retention in the tube, and improving drug absorption efficiency.

[0079] 5. Relief ports with a mesh-like distribution

[0080] The uniformly distributed drug release ports 121c allow the drug to be released evenly from all directions of the sustained-release tube, covering the entire inner wall of the lacrimal sac and ensuring that all lesions in the lacrimal sac can be exposed to an effective amount of drug, thus improving the comprehensiveness and consistency of treatment.

[0081] 6. Sustained-release tube adapted to the lacrimal sac structure

[0082] The expansion section 121a and contraction section 121b of the drug release tube 121 are adapted to the irregular internal structure of the lacrimal sac, can fit tightly against the lacrimal sac wall, reduce the gap between the tube and the lacrimal sac, prevent the drug from being lost from the gap, and improve the drug utilization rate.

[0083] 7. Flexible material piping

[0084] The circulating flow tubing 1, made of flexible material, has good flexibility and extensibility, and can naturally deform with the patient's blinking, head turning and other movements, avoiding the compression or scratching of the lacrimal canaliculi, lacrimal sac and nasal passages by rigid tubing, and reducing the risk of mucosal damage.

[0085] 8. Precisely controlled drug delivery structure 32

[0086] The threaded engagement between the screw 321 and the pusher disc 322, combined with the limiting function of the internal tooth slide 333, enables precise control of the drug delivery speed, ensuring that the drug is released uniformly at the set rate, meeting the therapeutic dosage requirements.

[0087] 9. Stable power transmission

[0088] The addition of the transmission gear 323 makes the power transmission between the screw 321 and the drive component 31 more stable. The speed of pushing medicine can be flexibly adjusted by adjusting the gear ratio of the transmission gear 323 to adapt to the speed requirements of different drive components 31.

[0089] 10. Intelligent closed-loop control

[0090] The pressure sensor monitors the internal pressure of the drug tube 33 in real time, and the control component adjusts the speed of the drive component 31 according to the pressure data, forming a closed-loop control of "pressure monitoring-speed adjustment" to ensure the safety of treatment and the stability of drug delivery effect.

[0091] 11. Convenient medication refill port 334

[0092] The drug replenishment port 334 on the side wall of the drug tube 33 allows for direct drug replenishment without disassembling the equipment or interrupting drug administration, avoiding treatment interruption caused by replacing the drug tube 33 and ensuring continuous drug administration.

[0093] 12. Comfortable headband support 2

[0094] The headband 2, with its eyeglass frame structure or elastic headband structure, conforms to daily wearing habits, is easy to wear and operate, and is aesthetically pleasing and discreet.

[0095] The lacrimal duct indwelling drug delivery wearable device of this invention solves the problems of low drug utilization, easy lacrimal duct adhesion, and poor controllability of drug delivery pressure in existing lacrimal duct indwelling medical devices by using a drug flow circuit and maintaining a constant pressure environment in the flow circuit. The drug flow circuit ensures that all tubes are always full, avoiding lacrimal duct adhesion; the drug sustained-release tube 121 accurately releases the drug, improving the therapeutic effect; the headband 2 and drive component 31 achieve standardized and precise drug delivery, reducing human operation errors. The dynamic flushing mechanism flushes inflammatory debris and secretions in the lacrimal duct through hydrodynamic action, reducing patient pain and infection risk. Intelligent closed-loop control and convenient drug replenishment port 334 further improve the ease of use of the device and the stability of the therapeutic effect. This innovative design not only improves the safety and efficiency of lacrimal duct treatment, but also significantly reduces patient pain and medical costs.

[0096] Therefore, this invention effectively overcomes the various shortcomings of the prior art and has high industrial application value.

[0097] The above embodiments are merely illustrative of the principles and effects of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by those skilled in the art without departing from the spirit and technical concept disclosed in the present invention should still be covered by the claims of the present invention.

Claims

1. A lacrimal duct indwelling drug delivery wearable device, characterized in that, include: A circulating flow pipeline (1) is provided, comprising a three-way tube (11), an indwelling tube (12), and a return tube (13). The three-way tube (11) comprises a first connecting tube (111), a second connecting tube (112), and a third connecting tube (113) that are interconnected at one end. The two ends of the return tube (13) are respectively connected to the other ends of the first connecting tube (111) and the second connecting tube (112). The indwelling tube (12) comprises a drug-releasing tube (121) and a circulating tube (122) that are interconnected at one end. The other end of the drug-releasing tube (121) is connected to the other end of the third connecting tube (113). The third connecting tube (113) is placed in the lacrimal canaliculus of the patient, the drug-releasing tube (121) is placed in the lacrimal sac, and the other end of the circulating tube (122) passes through the nasal passage of the patient and enters the return tube (13) to form a drug flow loop. The headband (2) and the drug delivery assembly (3) disposed on the headband (2) include a drive (31), a drug tube (33), and a drug delivery structure (32). The drug tube (33) is loaded with a drug. One end of the drug tube (33) is simultaneously connected to both ends of the return pipeline (13). The drive (31) drives the drug delivery structure (32) to move according to the drug release set rate, so that the drug in the drug tube (33) is simultaneously squeezed into both ends of the return pipeline (13). The drug enters the drug sustained-release tube (121) through the first connecting tube (111) and the second connecting tube (112) to maintain the drug pressure in the drug flow circuit, keep each pipeline in a full state, prevent lacrimal duct adhesion, and at the same time use the drug sustained-release tube (121) to release the drug to treat the affected area.

2. The lacrimal duct indwelling drug delivery wearable device according to claim 1, characterized in that: The drug release tube (121) has several drug release ports (121c) on its tube wall.

3. The lacrimal duct indwelling drug delivery wearable device according to claim 1, characterized in that: The circulating flow pipelines (1) are all made of flexible materials.

4. The lacrimal duct indwelling drug delivery wearable device according to claim 1, characterized in that: The drug-pushing structure (32) includes a screw (321) and a pusher toothed disc (322) adapted to the inner diameter of the drug tube (33). The other end of the drug tube (33) is sealed by a cover plate (331). The screw (321) is located at the central axis of the drug tube (33), and one end of the screw (321) is rotatably mounted on the cover plate (331). The pusher toothed disc (322) is sleeved on the other end of the screw (321). The end is threadedly connected to the screw (321). The inner wall of the medicine tube (33) is provided with an inner tooth slide (333) that engages with the outer teeth (322a) of the push tooth disc (322). The drive member (31) drives the screw (321) to rotate, causing the push tooth disc (322) to slide along the inner tooth slide (333), thereby using the push tooth disc (322) to squeeze the medicine from the medicine tube (33) into the return pipeline (13).

5. The lacrimal duct indwelling drug delivery wearable device according to claim 4, characterized in that: The drug pushing structure (32) also includes a transmission gear disk (323). One end of the screw (321) passes through the cover plate (331) and is connected to the transmission gear disk (323). The driving member (31) drives the transmission gear disk (323) to rotate, thereby driving the screw (321) to rotate.

6. The lacrimal duct indwelling drug delivery wearable device according to claim 5, characterized in that: The drug delivery assembly (3) further includes an active gear disk (311), which is disposed on the output shaft of the drive member (31) and meshes with the transmission gear disk (323). The active gear disk (311) drives the screw (321) to rotate through the transmission gear disk (323).

7. The lacrimal duct indwelling drug delivery wearable device according to claim 1, characterized in that: The side wall of the drug tube (33) has a drug replenishment port (334) for replenishing the drug tube (33).

8. The lacrimal duct indwelling drug delivery wearable device according to claim 1, characterized in that: The headband (2) is an eyeglass frame structure.

9. The lacrimal duct indwelling drug delivery wearable device according to claim 1, characterized in that: The lacrimal duct indwelling drug delivery wearable device also includes a pressure sensor and a control component electrically connected to the drive (31). The pressure sensor is disposed in the drug tube (33) and connected to the control component. The control component controls the rate at which the drive (31) releases the drug based on the drug internal pressure obtained by the pressure sensor and a preset pressure.

Images